# Mesenchymal Stem Cells for Prevention of Bronchopulmonary Dysplasia in Infants

> **NCT03631420** · PHASE1 · RECRUITING · sponsor: **Meridigen Biotech Co., Ltd.** · enrollment: 9 (estimated)

## Conditions studied

- Bronchopulmonary Dysplasia

## Interventions

- **BIOLOGICAL:** Human Umbilical Cord Derived-Mesenchymal Stem Cells

## Key facts

- **NCT ID:** NCT03631420
- **Lead sponsor:** Meridigen Biotech Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2018-10-26
- **Primary completion:** 2025-12-31
- **Final completion:** 2027-07-31
- **Target enrollment:** 9 (ESTIMATED)
- **Last updated:** 2023-12-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03631420

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03631420, "Mesenchymal Stem Cells for Prevention of Bronchopulmonary Dysplasia in Infants". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03631420. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*